# A Study of Rituximab in Combination With Chemotherapy in Relapsed/Refractory Follicular Lymphoma

> **NCT02472756** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 41 (actual)

## Conditions studied

- Lymphoma, Follicular

## Interventions

- **DRUG:** Chemotherapy
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02472756
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09-19
- **Primary completion:** 2014-05-30
- **Final completion:** 2014-05-30
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2017-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02472756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02472756, "A Study of Rituximab in Combination With Chemotherapy in Relapsed/Refractory Follicular Lymphoma". Retrieved via MORVS 2026-10-15 from https://api.morvs.ai/clinical/NCT02472756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*